Loading clinical trials...
Loading clinical trials...
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT06487481 · Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), and more
NCT07585006 · Tobacco-Related Carcinoma, Addiction
NCT07287098 · Breast Neoplasms
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Santa Monica, California
Pfizer Investigational Site
Philadelphia, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions